Old Web
English
Sign In
Acemap
>
authorDetail
>
Muhammad Jalaluddin
Muhammad Jalaluddin
Novartis
Medicine
Hematologic Response
Complete Hematologic Response
Phases of clinical research
Leukemia
2
Papers
6
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Evaluation of minimal residual disease in relapsed/refractory multiple myeloma patients treated with venetoclax or placebo in combination with bortezomib and dexamethasone: BELLINI study analyses.
2020
Journal of Clinical Oncology
Philippe Moreau
Simon J. Harrison
Michele Cavo
Javier de la Rubia
Rakesh Popat
Vania Hungria
Hans Salwender
Kenshi Suzuki
Inho Kim
Andrew Spencer
Michael ODwyer
Wan-Jen Hong
Muhammad Jalaluddin
Xiaoqing Yang
James Michael Pauff
Paulo Maciag
Jeremy A. Ross
Shaji Kumar
Show All
Source
Cite
Save
Citations (1)
A Phase II Study of Oral Panobinostat (LBH589) in Accelerated Phase (AP) or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Patients Resistant to ≥2 BCR-ABL Tyrosine Kinase Inhibitors
2008
Blood
François Guilhot
Viviane Dubruille
Aleksander B. Skotnicki
Andrey Hellmann
Jila Shamsazar
Priscille Bourquelot
Muhammad Jalaluddin
Martha Li
Elisabetta Abruzzese
Luke Akard
Show All
Source
Cite
Save
Citations (5)
1